2022 World Conference on Lung Cancer (ePosters)-EP08.02-141. Our' EGFR population

Pdf Summary

This document presents the results of a retrospective analysis of patients with advanced non-small cell lung cancer (NSCLC) and mutant epidermal growth factor receptor (mEGFR) treated at a secondary hospital in Portugal between 2014 and 2021. The study aimed to evaluate the demographic characteristics, treatments, and outcomes of these patients. Molecular testing was performed on all patients with adenocarcinoma and squamous carcinoma who were non-smokers or light smokers. The study period was divided into two phases, with different molecular testing methods used.<br /><br />The results indicate that patients who received subsequent tyrosine kinase inhibitor (TKI) therapies, with or without chemotherapy (ChT) and other systemic regimens, had better outcomes. However, patients who received osimertinib as a first-line treatment had shorter progression-free survival (PFS) and overall survival (OS). Several factors may contribute to this, including a lack of targeted therapy options after osimertinib, unidentified mechanisms of resistance, the high performance status of patients precluding other systemic therapies, and specific patient characteristics associated with a worse prognosis. The authors suggest the need for more clinical trials recruiting patients who progress after osimertinib and ChT.<br /><br />The demographic data of the patient population showed that a majority of patients were non-smokers (70.6%), with a smaller percentage being smokers (21.6%) or light smokers (7.84%). The median age of patients was 69 years, and the age range was 46 to 89 years. A total of 832 thoracic tumors were included in the analysis.<br /><br />In terms of treatment and outcomes, osimertinib was the most commonly used first-line therapy, with a PFS of 4.6 months and OS of 39.12 months. Some patients received a combination of TKI and platinum-based ChT, with half of them also receiving various ChT and immunotherapy regimens, resulting in an OS of 30.99 months. A small percentage of patients died before starting treatment, while others started ChT while waiting for TKI approval or began immunotherapy.<br /><br />The study also provides specific data on the outcomes associated with different types of mutations in the EGFR gene. Overall, the results suggest the need for further research and clinical trials to improve treatment options for patients with advanced NSCLC and mEGFR mutations.

Asset Subtitle

Sofia Campos Silva

Meta Tag

Speaker Sofia Campos Silva

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective analysis

non-small cell lung cancer

mEGFR

Portugal

molecular testing

osimertinib

progression-free survival

overall survival

targeted therapy options

clinical trials